Allergic Bronchopulmonary Aspergillosis–A Luminal Hypereosinophilic Disease With Extracellular Trap Cell Death

Shigeharu Ueki 1*, Akira Hebisawa 2, Masashi Kitani 2, Koichiro Asano 3 and Josiane S. Neves 4

1 Department of General Internal Medicine and Clinical Laboratory Medicine, Akita University Graduate School of Medicine, Akita, Japan, 2 Clinical Research Center and Pathology Division, National Hospital Organization Tokyo National Hospital, Tokyo, Japan, 3 Division of Pulmonary Medicine, Department of Medicine, Tokai University School of Medicine, Kanagawa, Japan, 4 Institute of Biomedical Sciences, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil

Allergic bronchopulmonary aspergillosis (ABPA) is characterized by an early allergic response and late-phase lung injury in response to repeated exposure to Aspergillus antigens, as a consequence of persistent fungal colonization of the airways. Here, we summarize the clinical and pathological features of ABPA, focusing on thick mucus plugging, a key observation in ABPA. Recent findings have indicated that luminal eosinophils undergo cytolytic extracellular trap cell death (ETosis) and release filamentous chromatin fibers (extracellular traps, ETs) by direct interaction with Aspergillus fumigatus. Production of ETs is considered to be an innate immune response against non-phagocytable pathogens using a “trap and kill” mechanism, although eosinophil ETs do not promote A. fumigatus damage or killing. Compared with neutrophils, eosinophil ETs are composed of stable and condensed chromatin fibers and thus might contribute to the higher viscosity of eosinophilic mucus. The major fate of massively accumulated eosinophils in the airways is ETosis, which potentially induces the release of toxic granule proteins and damage-associated molecular patterns, epithelial damage, and further decreases mucus clearance. This new perspective on ABPA as a luminal hypereosinophilic disease with ETosis/ETs could provide a better understanding of airway mucus plugging and contribute to future therapeutic strategies for this challenging disease.

Keywords: eosinophil, extracellular traps, extracellular trap cell death, allergic bronchopulmonary aspergillosis, inflammation, mucus plugs, ETosis, NETosis

INTRODUCTION

Allergic bronchopulmonary aspergillosis (ABPA) is a disease entity first proposed by Hinson and colleagues as bronchopulmonary aspergillosis in 1952 (1). ABPA develops mainly in adolescent and adult patients with asthma or cystic fibrosis. It has been estimated that 2.5% (0.7–3.5%) of adult patients with asthma suffer from ABPA (2). Clinically, it is characterized by peripheral blood eosinophilia, increased levels of serum IgE, an immediate skin reaction and/or specific IgE/IgG antibodies to Aspergillus fumigatus due to type I and III hypersensitivity reactions, and
radiographic findings including pulmonary opacities, central bronchiectasis, and mucus plugs (3–5). Systemic corticosteroids and/or anti-fungal drugs are effective, although approximately half of ABPA patients experience relapse (6, 7).

Besides blood eosinophilia, a massive accumulation of eosinophils and clustering of these immune cells in the bronchial lumen, resulting in bronchial impaction, are hallmarks of ABPA. Clinically, this has been defined by different terms depending on the context, such as “allergic mucin,” “high attenuation mucus,” or “allergic mucus plugs.” Considerable evidence has indicated the close association between the sputum eosinophil count and/or the eosinophil granule protein concentration and asthma severity (8, 9), although much less attention has been paid to luminal eosinophils (and their lytic components) in ABPA. This may be simply because of the lack of an explicit relationship and/or the difficulties in measuring protein concentrations due to the inspissated bronchial secretions. In this review, we discuss the clinical features of ABPA, focusing on new insights into the fate of eosinophils and their “cell debris” in the airways.

**FUNGUS IN THE AIRWAYS**

Germination and saprophytic growth of fungi in the mucus are interesting and unique features of ABPA. *Aspergillus fumigatus* is the major causative fungus of ABPA, but other *Aspergillus* spp., such as *A. flavus*, *A. niger*, and *A. oryzae*, can also cause ABPA, although less frequently. *Schizophyllum commune*, a filamentous basidiomycete commonly found on the rotten wood of trees, can cause similar pathology and a condition known as allergic bronchopulmonary mycosis (ABPM) (7, 10–12). Because fungal hyphae are immunologically active expressing and releasing various proteases and pathogen-associated molecular patterns (13–15), repeated exposures to airborne fragments of fungal hyphae, either dead or alive, can cause asthma and hypersensitivity pneumonitis. For the development of ABPM, by contrast, inhalation of viable fungi as conidia, not their hyphae fragments, and their germination in the lower airways is essential. *A. fumigatus* has advantages for the development of ABPA/ABPM over other fungi because of the small size of its conidia (3–6 μm) and thermophlicity (16). The conidia of *S. commune* are also small (3–4 μm), and prefer a relatively high temperature (30–35°C) to germinate (17). *A. fumigatus* conidia are also known for their high dispersibility due to their remarkable hydrophobicity (18).

Unlike fungal infections, germinated hyphae cannot penetrate the lung tissues in the presence of a normal immune system and bronchial structure. Therefore, *A. fumigatus* remains in the mucus plugs of the bronchi. Compared with other fungi, *A. fumigatus* has another advantage in this process in that it induces the Muc5ac gene, one of the mucin genes, and mucus production in bronchial epithelial cells (19). Induction of Muc5ac gene expression is dependent on the high serine protease activity of *A. fumigatus*, which activates membrane-bound TNFα-converting enzyme and TGF-α, stimulating epidermal growth factor receptors. Compared with *A. fumigatus*, other fungi, such as *Penicillium* and *Alternaria*, and other *Aspergillus* spp., such as *A. flavus* and *A. niger* have lower serine protease activity (19, 20).

**RADIOGRAPHIC FEATURES OF ABPA**

In the first description of ABPA, Hinson and colleagues advocated that the features of ABPA included (i) wheezing and blood eosinophilia, (ii) repetitive infiltrations visible on chest X-ray, and (iii) “allergic” (eosinophilic) mucus plugs with fungal hyphae (AMwF) (1). In 1967, Scadding (21) reported the presence of central bronchiectasis by bronchography, with the initial mucus-filled bronchi being less apparent but bronchial ectasis remaining. The diagnostic criteria for ABPA in the pre-computerized tomography era, proposed by Rosenberg and Patterson (22), included pulmonary opacities and central bronchiectasis.

Currently, the radiographic features of ABPA include bronchiectasis, mucus impaction, pulmonary opacities, mosaic attenuation, centrilobular nodules, tree-in-bud opacities, and pleuropulmonary fibrosis (3). Pulmonary opacities, which are usually transient, are frequently observed during the course of the disease, with 89% of ABPA cases with bronchiectasis demonstrating pulmonary opacities/ground grass attenuation in a nationwide survey in Japan (7); however, this is not classed as a specific feature of this disease. Central bronchiectasis with peripheral tapering of bronchi has been considered as a relatively specific finding for ABPA, but bronchiectasis can extend to the peripheral bronchi in 33–63% of cases (23, 24). Mucus plugs in the bronchi are common in ABPA, and may present as high attenuation mucus (HAM) with a CT density higher than the values of paraspinal skeletal muscle (25) or 70 Hounsfield units (26). Magnetic resonance imaging of HAM showed hypodense lesions in T1- and T2-weighed images, suggesting that the mucus is desiccated or inspissated (27). HAM can be observed in more than half of the cases with mucus plugs due to ABPA (7, 23), and is more specific for this disease. The presence of HAM also correlates with a higher number of eosinophils in the peripheral blood and greater susceptibility to disease relapse (6, 28).

**CLINICOPATHOLOGICAL FEATURES OF ABPA**

Regarding the pathological features of ABPA, Katzenstein and colleagues emphasized the presence of AMwF, bronchocentric granulomatosis with tissue eosinophilia (BrCG-eo), eosinophilic bronchiolitis, and eosinophilic pneumonia (29). In 1988, Bosken and coworkers indicated, based on the investigation of surgically resected specimens, that mucoid impaction of bronchi with allergic mucin or BrCG-eo, together with fungal hyphae detected in the lesion, were sufficient for the diagnosis of ABPA/ABPM (30). However, the diagnostic criteria proposed by Rosenberg and
Patterson (22) excluded pathological findings; instead, clinical, radiological, and laboratory findings, especially allergy tests, were included.

AMwF was detected in the biopsy samples by bronchoscopy, expectorated airway secretions, and the resected lungs. AMwF has been described by pathologists as follows (31, 32). “AMwF could be found in any bronchi of any lobes, including lobar and segmental bronchi and 3rd–5th bifurcated small bronchi. AMwF was typically white-yellowish, dark-yellowish, or yellow-greenish in color, and sticky with elastic soft or elastic hard in consistency. The shape ranged from branching and clubbing to lumpy. The H&E stained section of the AMwF demonstrated concentric multiple layers consisting of eosinophils, Charcot-Leyden crystals, and fibrin (32, 33). The eosinophils might be viable, necrobiotic (with pyknotic nuclei and nuclear dusts) or necrotic. The latter two types formed inspissated eosinophil aggregates with indistinct cell margins and occasionally exhibited many fissures likely due to dehydration inside of AMwF, demonstrating ‘fir-tree structure’ (33). Fungi were usually found in the clusters of eosinophils as fragmented hyphae or branching septate hyphae, and occasionally in the mucus surrounding the eosinophil clusters. While fungi floats in the air as unicellular spores, they reside in the AMwF as multicellular hyphae, suggesting the proliferation of fungi.”

Central bronchiectasis and peripheral lung lesions in ABPM were suggested as secondary pathological changes after the formation of AMwF. BrCG-eo, eosinophilic bronchiolitis, and eosinophilic pneumonia were found to be in the airways peripheral to the AMwF plugs, previously described as follows (32). “The investigation of the resected lungs of ABPM patients revealed the airway walls plugged by AMwF were invaded with eosinophils and small round cells including plasma cells and were ulcerated, resulting in eosinophilic infiltration into the allergic mucin. The intense inflammation in the bronchial walls destructed and dissipated airway structures i.e., elastic fibers and smooth muscles, and even bronchial cartilages. Central bronchiectasis could be caused by the vulnerability of diseased bronchial walls and by expanding AMwF. In the exudate from BrCG-eo and eosinophilic bronchiolitis, inspissated eosinophil aggregates, fir-tree structures and fungi were detected, similar to the AMwF. However, the inspissated eosinophil aggregates and fir-tree structures were fragmented and the number of fungi was smaller than that in the central lesions of AMwF (30–33). These findings suggested that the peripheral lung lesions might be formed by the bronchogenic spread of AMwF to the peripheral lung.” Thus, careful morphological analysis has indicated the AMwF is an initial and crucial step in the development of ABPA.

**EOSINOPHIL EXTRACELLULAR TRAP CELL DEATH (ETOSIS) AND EXTRACELLULAR TRAPS**

Eosinophils are bone marrow-derived, short-lived, non-dividing granulocytes that have been implicated as integral components of allergic airway inflammation. Eosinophils contain ~200 granules per cell (34), which are preformed stores of the specific granule proteins (35). The highly cationic granule proteins possess cytotoxicity by disrupting the integrity of lipid bilayers, exerting neurotoxic properties, RNase activities, and participating in the generation of reactive oxidants and radical species (36, 37). Since eosinophil degranulation does not occur in the circulation (38), it is critical to understand the actual mode of degranulation and cell fate in the airways. Our recent studies indicated eosinophil cell-death mediated degranulation, i.e., eosinophil ETosis, which might play an important role in the generation of mucus plugs (39, 40).

In 2004, Brinkman and colleagues provided the first evidence that neutrophils release filamentous chromatin structures, i.e., neutrophil extracellular traps (NETs) (41). A subsequent study revealed that the novel cell death process mediates the release of NETs and was designated NETosis (42). NETosis has unique features that are different from apoptosis and necrosis. Unlike apoptosis, nuclear DNA fragmentation is spared during the process of NETosis. Histone citrullination induces chromatin decondensation and granules are intracellularly disrupted before plasma membrane disintegration, thereby NETs are associated with various antimicrobial molecules (including histones, elastase, myeloperoxidase, cathepsin, and lactoferrin). Once NETs are released, they immobilize and potentially kill pathogens (41, 43, 44). Based on this, roles for these structures in preventing microbial spread and in creating an antimicrobial environment have been postulated.

Since chromatin traps are cytolytically released by other leukocytes, such as macrophages (45) and mast cells (46, 47), “ETosis” has been proposed as a similar cell death pathway (48). Extracellular trap (ET) formation is now considered to be a common mechanism of the innate immune system in vertebrates (49). A recent report showed that even invertebrate cells are capable of ETosis, indicating an ancient and evolutionary conserved mechanism (50). Eosinophil ETosis (EETosis) was first reported as a mechanism of “cytolysis” (also called lytic degranulation, necrosis, primary lysis, and eosinophil lysis) that has been observed (but often overlooked) in eosinophilic inflammatory diseases (35). This finding indicates that eosinophil cytolysis does not represent a process of passive/accidental necrosis, rather eosinophils are actively selecting their death program at the inflammatory site. The process of EETosis is akin to that of neutrophils but notably differs in that intact granules are released extracellularly (35, 51–53).

It is well-established that the process of leukocyte activation and ET release plays a role in health and disease, including innate immunity, autoimmunity, metabolic disorders, malignancies, and coagulation (44, 46, 54–57). Excess production of ETs could be pathogenic (49); for instance, large amounts of NETs contribute to the thickness of airway fluids from patients with cystic fibrosis (58). Inhalation of recombinant human DNase improved lung function in cystic fibrosis patients, indicating the pathogenicity of NETs (58–60). Similar to NETs, EETs provide a sticky scaffold for secretions, a fact confirmed by the decrease in viscosity following disruption of EET polymers with DNase (61). Recently, we have shown abundant EETs associated with clusters of cell-free extracellular granules in the bronchial mucus plugs of ABPA patients (39, 40). We also observed a drastic decrease in EETs in the bronchoscopically-obtained secretions from an
ABPA patient after corticosteroid treatment, which correlated with clinical improvements (40).

It is noteworthy that NETs and EETs have different attributes in terms of stability and structure. The protein content of ETs plays an important role in its mechanical properties (62). Compared with neutrophils, eosinophils contain far less proteases, and thus eosinophil chromatin is spared from endogenous protease digestion (61, 63). Neutrophil elastase promotes the chromatin decondensation of NETs by proteolytic processing of histones (64). In vitro, NETs deteriorated within 24 h, whereas EETs were stable for at least 7 days (61). Electron microscopy showed that released NETs consisted of 5–10-nm smooth stretches (composed of stacked cylindrical nucleosomes) and 25–50-nm globular domains (41, 65), although EETs consisted mostly of chromatin fibers with diameters of 25–35 nm in conjunction with larger fibers (35). In terms of innate immune responses, staunch fibers might offer an advantage by immobilizing and hampering the progression of large parasites (66), and may also pathologically contribute to the highly viscous nature of eosinophil-dominant airway secretions, as clinically observed in ABPA, but also in other diseases, such as eosinophil chronic rhinosinusitis (51, 61), eosinophilic otitis media (63, 67), and severe asthma (40, 68).

There is evidence in vitro that human eosinophils rapidly activate in response to various stimuli by releasing mitochondrial DNA via a non-cytolytic mechanism (69, 70). The mitochondrial DNA would be present in mucus plugs since EETosis liberates total cellular contents through plasma membrane disintegration. However, mitochondrial DNA, lacking the histone and nucleosome structure, is only 16 kbp in size, constituting <1% of total cellular DNA (e.g., genomic DNA has 3.2 billion bp, which equates to 2 m in length/cell) (71). In addition, human eosinophils contain a small number of mitochondria (~30/cell) (72). Therefore, nuclear-derived chromatin fibers are a major component contributing to viscosity (35), as evidenced by positive staining of airway EETs with specific antibodies against histones/citrullinated histones (39, 61).

### A. FUMIGATUS INDUCED EOSINOPHIL ETOSIS

The immunopathological mechanisms that underlie the molecular interactions between *A. fumigatus* and eosinophils are also of interest (see review (73)). Our *in vitro* studies have shown that ETs are released by lytic human eosinophils in direct response to *A. fumigatus* (39). When human eosinophils were co-cultured with *A. fumigatus*, EETs were released in a time and ratio (fungus: cell) dependent manner (39).

Unlike necrosis, ETosis is an active form of cell death and is frequently accompanied by the production of reactive oxygen species (ROS) (35, 41, 43, 52, 69, 70, 74–76); however, we observed that human eosinophils release EETs *in vitro* in response to *A. fumigatus* in a ROS-independent manner (39). Regarding *Aspergillus* specifically, neutrophils are described to respond to different morphotypes of this fungus by releasing NETs in a ROS-dependent process (77–79). However, the ROS-independent release of NETs was observed when stimulated by bacteria (80), parasites (81), fungi (*Candida* and *Paracoccidioides brasiliensis* conidia) (82, 83), and other stimuli (84–86). The participation of ROS in the process of ETosis might be essentially dependent on the stimuli, time point, or microorganisms examined.

Mechanistically, *A. fumigatus* induced EETosis *in vitro* is a process dependent on the Syk tyrosine kinase pathway (known to mediate cell signaling via different classes of receptors involved in fungus recognition) and adhesion molecule CD11b β-integrin (which recognizes β-glucan, a molecular pattern commonly found in the cell wall of fungi) (39). Consistent with these findings, CD11b has been described to play an important role in eosinophil interactions with the fungus *Alternaria alternata* (87). Previous studies with eosinophils and *A. alternata* suggest a critical role for the CD11b I domain in eosinophil activation and degranulation, but not for the lectin domain, which recognizes the β-glucan (87). In neutrophils, both the C-type lectin receptor dectin-1 and the β-integrin CD11b/CD18 (CR3) have been implicated in the recognition of β-glucans on the cell surface of *A. fumigatus* (79, 88, 89). However, we did not detect the expression of dectin-1 protein in human blood eosinophils (39).

Airway eosinophils display enhanced responses to a variety of ligands and become further activated to degranulate (90, 91). Human eosinophils undergo ETosis in response to immobilized IgG or IgA (used as *in vitro* defined models of immunoglobulin-coated pathogens including parasites), calcium ionophore, IL-5/GM-CSF with platelet activating factor, or phorbol myristate acetate to liberate ETs (35, 68, 92). In addition to the direct response to *A. fumigatus*, it is possible that locally produced immunoglobulins, cytokines, and other mediators could activate eosinophils to induce EETosis. Indeed, a recent study indicated that IgG-type autoantibodies were present in the airways of patients with severe eosinophilic asthma, potentially induced by the release of EETs (68). It is also noteworthy that biological molecules associated with the fungal cell wall, such as chitin and β-glucan from *Aspergillus* species, induce eosinophilic Th2 inflammation in mouse lungs (93–95).

### LUMINAL EOSINOPHILS AND ETOSIS MATTER

EETs exhibited intimate contact with *A. fumigatus* conidia and with cell-free extracellular granules, indicating that EETs provide an adhesive surface for organelle and microorganism entrapment (39). The highly hydrophobic surface of *A. fumigatus* might be easily entrapped by EETs, since EETs ensnare microorganisms mainly via hydrophobic interactions (39, 61). It has been reported that NETs may efficiently kill microbial pathogens (96–99); however, several fungi may resist the antimicrobial effect of NETs (79, 83, 100, 101).

Interestingly, our study revealed that human EETs did not promote the damage or killing of *A. fumigatus* (39). Eosinophils exhibit killing activity against different pathogens both *in vitro* and in experimental models (reviewed in (102)). *In vitro*, Yoon
and colleagues demonstrated that human eosinophils release their cytotoxic granule proteins in response to A. alternata and kill the fungus in a contact-dependent manner (87). Mouse bone marrow-derived eosinophils exhibited killing activity against A. fumigatus in vitro, which did not require cell contact (103). By contrast, using a Th2-dominant murine model of chronic invasive aspergillosis, eosinophil-deficient mice showed decreased morbidity and improved clearance of A. fumigatus (94). Intriguingly, studies based on mouse experimental models revealed that Th2-type immunity to chronic fungi exposition is generally accompanied by detrimental allergic inflammation, including tissue eosinophilia, goblet cell hyperplasia, and airway remodeling, but no signs of hypoxic or invasive fungal growth were reported at any time after conidia challenge (104). Thus, the development of an animal model showing fungal colonization of the airways similar to that observed in ABPA pathology is still lacking. It remains unclear whether these discrepancies are due to the differences between mouse and human eosinophils (105) and/or experimental settings. Nevertheless, A. fumigatus resistance to EET killing activity might be an important feature of ABPA pathogenesis, possibly explaining the previously suggested “innate immunological defect” in this disease (3).

The rheological properties of mucus and the mucociliary transport system function as a self-cleaning mechanism for the respiratory tract (106). However, difficult-to-remove eosinophilic airway secretions are associated with disease severity (107, 108). As described above, the lower protease content and stable chromatin traps of eosinophils contribute to airway mucus viscosity. Most recently, Dunican and coworkers indicated that oxidants generated by eosinophil granule protein oxidize cysteine thiol groups to stiffen airway mucus (109).

We propose that EETosis contributes significantly to the fate of luminal eosinophils and plays a critical role in the pathogenesis of ABPA (Figure 1). Under Th2 conditions, blood eosinophils actively accumulate in the airway tissue. Eosinophils are usually eliminated by migration into the airway lumen followed by mucociliary clearance (110). Unlike apoptosis that produces fragmented DNA, luminal eosinophils undergo ETox by direct interaction with fungi and/or local stimuli to release a sticky chromatin structure. EETs contribute to the increased viscosity of mucus rather than the direct elimination of fungi. Eosinophil cytolysis also releases intact granules and a wide range of nuclear and cytosolic damage-associated molecular patterns (92). Free granules may act as a reservoir of toxic granule proteins and secretion-competent extracellular organelles (35, 111). Perpetuating epithelial damage may inhibit the effectiveness of ciliary beating, thereby decreasing mucus transport and also resulting in the release of alamins and further eosinophilic inflammation. Thus, EETosis might promote a perpetuating cycle of thickening secretions (51). However, this new perspective requires further evaluation.

CONCLUDING REMARKS

As reviewed by Persson and Uller (112), cytolysis has often been overlooked by researchers, although several clinical studies illustrated that cytolysis accounted for a major proportion of bronchial eosinophils in severe and lethal asthma (112). Because apoptosis is a rare event among tissue-migrated eosinophils, ETox-mediated cytolysis and luminal entry are likely to be the major fates of these cells. Indeed, Charcot–Leyden crystals, often observed in mucus plugs, were generated in association with the EETosis process (53). Considering the clinical features of ABPA, it is conceivable that increased eosinophil turnover, rather than prolonged lifespan, might be a major cause of luminal eosinophilia. It should be recognized that EETosis-mediated cytolysis and EETs are potentially important therapeutic targets in ABPA, as well as in other eosinophilic inflammatory diseases.

AUTHOR CONTRIBUTIONS

SU wrote and finalize the manuscript. AH and MK contributed pathological part; KA contributed clinical part. JN wrote cell biology part.

ACKNOWLEDGMENTS

The authors are grateful to Noriko Tan, Satomi Misawa, and Kaori Kato (Akita University) for their outstanding assistance.
This study was funded in part by a Research Grant on Allergic Disease and Immunology from the Japan Agency for Medical Research and Development under Grant Number JP18ek0410026, Japanese Society of Laboratory Medicine Found for the Promotion of Scientific Research, and JSPS KAKENHI 15KK0329, 16K08926 (SU). JN thanks the Brazilian agencies for the Promotion of Scientific Research, and JSPS KAKENHI for Medical Research and Development under Grant Number 1002257.

REFERENCES

1. Hinson KF, Moon AJ, Plummer NS. Broncho-pulmonary aspergillosis; a review and a report of eight new cases. *Thorax* (1952) 7:317–33. doi: 10.1136/thx.7.4.317
2. Denning DW, Pleuvry A, Cole DC. Global burden of allergic bronchopulmonary aspergillosis with asthma and its complication chronic pulmonary aspergillosis in adults. *Med Mycol.* (2013) 51:361–70. doi: 10.3109/13693787.2012.738312
3. Agarwal R, Chakrabarti A, Shah A, Gupta D, Meis JF, Guleria R, et al. Allergic bronchopulmonary aspergillosis: review of literature and proposal of new diagnostic and classification criteria. *Clin Exp Allergy* (2013) 43:850–73. doi: 10.1111/ce.a.12141
4. Knutsen AP, Bush RK, Demain JG, Denning DW, Dixit A, Fairs A, et al. Fungi and allergic lower respiratory tract diseases. *J Allergy Clin Immunol.* (2012) 129:280–91; quiz 292–3. doi: 10.1016/j.jaci.2011.12.970
5. Kosmidis C, Denning DW. The clinical spectrum of pulmonary aspergillosis. *Thorax* (2015) 70:270–7. doi: 10.1136/thoraxjnl-2014-206291
6. Agarwal R, Khan A, Gupta D, Aggarwal AN, Saxena AK, Chakrabarti A. An alternate method of classifying allergic bronchopulmonary aspergillosis based on high-attenuation mucus. *PLoS ONE* (2010) 5:e13534. doi: 10.1371/journal.pone.0015346
7. Oguma T, Taniguchi M, Shimoda T, Kamei K, Matsuse H, Habisawa A, et al. Allergic bronchopulmonary aspergillosis in Japan: a nationwide survey. *Allergol Int.* (2018) 67:79–84. doi: 10.1016/aj.al.2017.04.011
8. Mukherjee M, Nair P. Blood or sputum eosinophils to guide asthma therapy? *Lancet Respir Med.* (2015) 3:824–5. doi: 10.1016/S2213-2600(15)00419-1
9. Persson C, Uller L. Resolution of leucocyte-mediated mucosal diseases. A novel *in vivo* paradigm for drug development. *Br J Pharmacol.* (2012) 165:2100–9. doi: 10.1111/j.1476-5381.2011.01772.x
10. Kamei K, Urano H, Nagao K, Kuriyama T, Nishimura K, Miyaji M. Allergic bronchopulmonary mycosis caused by the basidiomycetous fungus *Schizopyllum commune*. *Clin Infect Dis.* (1994) 18:305–9. doi: 10.1093/clinids/183.3.150
11. Ishiguro T, Takayanagi N, Kagiyaama N, Shimizu Y, Yanagisawa T, Sugita Y. Clinical characteristics of biopsy-proven allergic bronchopulmonary mycosis: variety in causative fungi and laboratory findings. *Internal Med.* (2014) 53:1407–11. doi: 10.2169/internalmedicine.53.2230
12. Chowdhry A, Agarwal K, Kathuria S, Gaur SN, Randhawa HS, Meis JF. Allergic bronchopulmonary mycosis due to fungi other than *Aspergillus*: a global overview. *Crit Rev Microbiol.* (2014) 40:30–48. doi: 10.3109/1040841X.2012.754401
13. Romani L. Immunity to fungal infections. *Nat Rev Immunol.* (2011) 11:275–88. doi: 10.1038/nri2939
14. Fukutomi Y, Taniguchi M. Sensitization to fungal allergens: resolved and unresolved issues. *Allergol Int.* (2015) 64:321–4. doi: 10.21693/aj.al.2015.05.007
15. Portnoy JM, Williams PB, Barnes CS. Innate immune responses to fungal allergens. *Carr Allergy Asthma Rep.* (2016) 16:62. doi: 10.1007/s11882-016-0643-4
16. Araujo R, Rodrigues AG. Variability of germinative potential among pathogenic species of *Aspergillus*. *J Clin Microbiol.* (2004) 42:4335–7. doi: 10.1128/ICM.42.9.4335-4337.2004
17. Imitaj A, Jayasinghe C, Lee GW, Kim HY, Shim MJ, Rho HS, et al. Physicochemical requirement for the vegetative growth of *Schizopyllum commune* collected from different ecological origins. *Mycobiology* (2008) 36:34–9. doi: 10.4489/MYCO.2008.36.1.034
18. Kwon-Chung KJ, Sugui JA. *Aspergillus fumigatus*: what makes the species a ubiquitous human fungal pathogen? *PloS Pathog.* (2013) 9:e1003743. doi: 10.1371/journal.ppat.1003743
19. Oguma T, Asano K, Tomomatsu K, Kodama M, Fukunaga K, Shiomi T, et al. Induction of mucin and MUC5AC expression by the protease activity of *Aspergillus fumigatus* in airway epithelial cells. *J Immunol.* (2011) 187:999–1005. doi: 10.4049/jimmunol.1002257
20. Alp S, Arikan S. Investigation of extracellular elastase, acid protease and phospholipase activities as putative virulence factors in clinical isolates of *Aspergillus species*. *J Basic Microbiol.* (2008) 48:331–7. doi: 10.1002/jobm.200703349
21. Scadding J. The bronchi in allergic aspergillosis. *Scand J Resp Dis.* (1967) 48:372–377.
22. Rosenberg M, Patterson R, Mintzer R, Cooper BJ, Roberts M, Harris KE. Clinical and immunologic criteria for the diagnosis of allergic bronchopulmonary aspergillosis. *Ann Intern Med.* (1977) 86:405–14. doi: 10.7326/0003-4819-86-4-405
23. Reiff DB, Wells AU, Carr DH, Cole PJ, Hansell DM. CT findings in bronchiectasis: limited value in distinguishing between idiopathic and specific types. *Am J Roentgenol.* (1995) 165:261–7.
24. Agarwal R, Khan A, Garg M, Aggarwal AN, Gupta D. Chest radiographic and computed tomographic manifestations in allergic bronchopulmonary aspergillosis. *World J Radiol.* (2012) 4:141–50. doi: 10.4329/wjr.v4.i.141
25. Agarwal R, Gupta D, Aggarwal AN, Saxena AK, Chakrabarti A, Jindal SK. Clinical significance of hyperattenuating mucoid impaction in allergic bronchopulmonary aspergillosis: an analysis of 155 patients. *Chest* (2007) 132:1183–90. doi: 10.1378/chest.07-0808
26. Phuyal S, Garg MK, Agarwal R, Gupta P, Chakrabarti A, Sandhu MS, Khandelwal N. High-attenuation mucus impaction in patients with allergic bronchopulmonary aspergillosis: objective criteria on high-resolution computed tomography and correlation with serologic parameters. *Carr Prbli Diagn Radiol.* (2016) 45:168–73. doi: 10.1067/cpradiol.2015.07.006
27. Garg MK, Gupta P, Agarwal R, Sodhi KS, Khandelwal N. MRI: a new paradigm in imaging evaluation of allergic bronchopulmonary aspergillosis. *Ann Radiol.* (2015) 59:1004–10. doi: 10.1016/j.ijiph.2011.08.006
28. Katzenstein AL, Liebow AA, Friedman PJ. Bronchocentric granulomatosis, mucoid impaction, and hypersensitivity reactions to fungi. *Am Rev Respir Dis.* (1975) 111:497–537.
29. Bosken CH, Myers JL, Greenberger PA, Katzenstein AL. Pathologic features of allergic bronchopulmonary aspergillosis. *Am J Surg Pathol.* (1988) 12:216–22. doi: 10.1097/00000478-198803000-00007
30. Aubry MC, Fraser R. The role of bronchial biopsy and washing in the diagnosis of allergic bronchopulmonary aspergillosis. *Mod Pathol.* (1998) 11:807–11.
31. Hebisenawa A, Tamura A, Kurashima A, Ookayashi C, Kawamura M, Maeda M, et al. Pathologic reconsideration on allergic bronchopulmonary aspergillosis and mycosis. *Nikon Kokyuki Gakkai Zasshi* (1998) 36:330–7.
32. Jelihovsky T. The structure of bronchial plugs in mucoid impaction, bronchocentric granulomatosis and asthma. *Histopathology* (1983) 7:153–67. doi: 10.1111/j.1365-2559.1983.tb02223.x
53. Ueki S, Tokunaga T, Melo RCN, Saito H, Honda K, Fukuchi M, et al. Eosinophil extracellular DNA traps in response to Aspergillus fumigatus. *J Allergy Clin Immunol.* (2018) 141:571–585 e7. doi: 10.1016/j.jaci.2017.07.048

54. Garcia-Romo GS, Caelli S, Vega B, Connolly J, Allantaz F, Xu Z, et al. Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus. *Sci Transl Med.* (2011) 3:73ra20. doi: 10.1126/scitranslmed.3001201

55. Khandpur R, Carmona-Roblero C, Vivekanandan-Giri A, Giziński A, Valyavali S, Knight JS. et al. NETs are a source of citrullinated autoantigens and stimulate inflammatory responses in rheumatoid arthritis. *Sci Transl Med.* (2013) 5:178ra40. doi: 10.1126/scitranslmed.3005580

56. Wang Y, Xiao Y, Zhong L, Ye D, Zhang J, Tu Y, et al. Increased neutrophil elastase and proteinase 3 and augmented NETosis are closely associated with beta-cell autoimmunity in patients with type 1 diabetes. *Diabetes* (2014) 63:4239–48. doi: 10.2337/db14-0480

57. Sollberger G, Tilley DO, Zychlinsky A. Neutrophil extracellular traps: the biology of chromatin externalization. *Dev Cell* (2018) 44:542–53. doi: 10.1016/j.devcel.2018.01.019

58. Manenzreiter R, Kienbenz F, Marcos V, Schlicher K, Krautgartner WD, Obermayer A, et al. Ultrastructural characterization of cystic fibrosis sputum using atomic force and scanning electron microscopy. *J Cyst Fibros.* (2012) 11:84–92. doi: 10.1016/j.jcf.2011.09.008

59. Yang CL, Chilvers M, Montgomery M, Nolan SJ. Dornase alfa for cystic fibrosis. *Paediatr Respir Rev.* (2016) 4:CD01127.

60. Pires RH, Felix SB, DELcea M. The architecture of neutrophil extracellular traps investigated by atomic force microscopy. *Nanoscale* (2016) 8:14193–202. doi: 10.1039/C6NR0316K

61. Ueki S, Ohta N, Takeda M, Moritoki Y, Hirokawa M, Matsuwa Y, et al. Eosinophil extracellular trap cell death-derived DNA traps: their presence in secretions and functional attributes. *J Allergy Clin Immunol.* (2016) 137:258–67. doi: 10.1016/j.jaci.2015.04.041

62. Pires RH, Felix SB, DELcea M. The architecture of neutrophil extracellular traps investigated by atomic force microscopy. *Nanoscale* (2016) 8:14193–202. doi: 10.1039/C6NR0316K

63. Ueki S, Ohta N, Takeda M, Moritoki Y, Hirokawa M. Eosinophilic otitis media: the aftermath of Eosinophil extracellular trap cell death. *Curr Allergy Asthma Rep.* (2017) 17:33. doi: 10.1007/s11882-017-0702-5

64. Papayannopoulos V, staab D, Zychlinsky A. Neutrophil elastase enhances sputum solubilization in cystic fibrosis patients receiving DNase therapy. *PLoS ONE* (2011) 6:e28526. doi: 10.1371/journal.pone.0028526

65. Urban CE, Ermert D, Schmid M, Abu-Abed U, Goosmann C, NACKen W, et al. Leucocyte-derived extracellular trap formation significantly contributes to *Haemonchus contortus* larval entrapment. *Parasit Vectors* (2015) 8:607. doi: 10.1186/s13071-015-1219-1

66. Ohta N, Ueki S, Konno Y, Hirokawa M, Kubota T, Tomioka-Matsutani S, et al. Eosinophil-derived DNA trap production in middle ear effusion is a common feature of eosinophilic otitis media. *Allergy* (2018) 73:401–7. doi: 10.1111/all.13674

67. Mukherjee M, Bulir DC, Radford K, Kjærsgaard M, Huang CM, Jacobsen EA, et al. Sputum autoantibodies in patients with severe eosinophilic asthma. *J Allergy Clin Immunol.* (2018) 141:1269–79. doi: 10.1016/j.jaci.2017.06.033

68. Youssef S, Gold JA, Andina N, Lee JJ, Kelly AM, Kozlowski E, et al. Catapult-like release of mitochondrial DNA by eosinophils contributes to antibacterial defense. *Nat Med.* (2008) 14:1041–6. doi: 10.1038/nm.1855

69. Brinkmann V, Reichard U, Goosmann C, Fauler B, Uhlemann Y, Weiss DS, et al. Neutrophil extracellular traps kill bacteria. *Science* (2004) 303:1532–3. doi: 10.1126/science.1092385

70. Chow OA, Von Kockritz-Blickwede M, Bright AT, Hensler ME, Zinkernagel RS, et al. Charcot-Leyden crystal formation is closely associated with competent eosinophil granules in humans. *Blood* (2013) 121:2074–83. doi: 10.1182/blood-2012-05-432088

71. Persson C, Ueki S. Lytic eosinophils produce extracellular DNA traps as well as free eosinophil granules. *J Allergy Clin Immunol.* (2018) 141:1164. doi: 10.1016/j.jaci.2017.05.047
ABPA-Luminal Hypereosinophilia With ETosis

Ueki et al.

72. Peachman KK, Lyles DS, Bass DA. Mitochondria in eosinophils: functional role in apoptosis but not respiration. *Proc Natl Acad Sci USA*. (2001) 98:1717–22. doi: 10.1073/pnas.98.4.1717

73. Figueiredo RT, Neves JS. Eosinophils in fungal diseases: an overview. *J Leukoc Biol*. (2018) 104:49–60. doi: 10.1002/jlb.4MR1117-473R

74. Yousefi S, Mahboudi H, Walshe CJ, Kozlowski E, Schmid L, Simon HU. Viable neutrophils release mitochondrial DNA to form neutrophil extracellular traps. *Cell Death Differ*. (2009) 16:1438–44. doi: 10.1038/cdd.2009.96

75. Remijis Q, Vanden Bergh T, Wirawan E, Asselbergh B, Parhoens E, De Rycke R, et al. Neutrophil extracellular trap cell death requires both autophagy and superoxide generation. *Cell Res*. (2011) 21:290–304. doi: 10.1038/cr.2010.150

76. Douda DN, Khan MA, Grasemann H, Palaniyar N. SK3 channel and influenced by hydrophobin rod. *PLoS Pathog*. (2010) 6:e1000873. doi: 10.1371/journal.ppat.1000873

77. Rohm MA, Grimm MJ, D’Auria AC, Almyroudis NG, Segal BH, Urban CF. NADPH oxidase promotes neutrophil extracellular trap formation in pulmonary aspergillosis. *Infect. Immun.* (2014) 82:1766–77. doi: 10.1128/IAI.00906-14

78. Gazendam RP, van Hamme JL, Tool AT, Hoogenboezem M, van den Berg B, Vlaminck S, Vauterin T, Hellings PW, Jorissen M, Acke F, Van Den Abeele S, et al. NADPH oxidase and myeloperoxidase in neutrophil extracellular traps. *Biochem Biophys Res Commun.* (2013) 431:2907–15. doi: 10.1016/j.bbrc.2013.01.024

79. Van Dyken SJ, Garcia D, Porter P, Huang X, Quinlan PJ, Blanc PD, et al. Fungal chitin from asthma-associated home environments induces eosinophilic lung infiltration. *Infect. Immun.* (2011) 81:588–96. doi: 10.1128/IAI.00979-11

80. Yoon J, Ponikau JU, Lawrence CB, Kita H. Innate antifungal immunity of human eosinophils mediated by a beta 2 integrin, CD11b. *J Innate Immun.* (2013) 5:285–93. doi: 10.1159/000345376

81. McCormick A, Heesemann L, Wagener J, Marcos V, Hartl D, Loeffler J, et al. Antibodies mediate formation of neutrophil extracellular traps against *Aspergillus fumigatus* in vitro and in infected lung tissue is dependent on invading neutrophils and influenced by hydrophobin rod. *PLoS Pathog*. (2010) 6:e1000873. doi: 10.1371/journal.ppat.1000873

82. Short KR, von Kockritz-Blickwede M, Langereis JD, Chew KY, Job ER, Armitage CW, et al. Antibodies mediate formation of neutrophil extracellular traps in the middle ear and facilitate secondary pneumococcal otitis media. *Infect. Immun.* (2014) 82:364–70. doi: 10.1128/IAI.01104-13

83. Van Dyken SJ, Mohapatra A, Nussbaum JC, Molofsky AB, Thornton EE, Ziegler SF, et al. Chitin activates parallel immune modules that direct distinct inflammatory responses via innate lymphoid type 2 and gammadelta T cells. *Immunity* (2014) 40:414–24. doi: 10.1016/j.immuni.2014.02.003

84. de Buhr N, Neumann A, Jerjomiceva N, von Kockritz-Blickwede M, Baums CG. *Streptococcus suis* DNoase SnAa contributes to degradation of neutrophil extracellular traps (NETs) and evasion of NET-mediated antimicrobial activity. *Microbiology* (2014) 160:385–95. doi: 10.1099/mic.0.072199-0

85. Th2-mediated immune pathology in human eosinophils. *Cytokine* (2016) 88:45–50. doi: 10.1016/j.cyto.2016.08.013

86. Yamauchi Y, Ueki S, Konno Y, Ito W, Takeda M, Nakamura Y, et al. The effect of hepatocyte growth factor on secretory functions in human eosinophils. *Eur Respir J*. (2011) 38:3251–60. doi: 10.1183/09031936.001026.x

87. King M. Experimental models for studying mucociliary clearance. *Front Immunol* (2013) 4:56. doi: 10.3389/fimmu.2013.00056

88. Clark K, Simson L, Newcombe N, Koskinen AM, Mattes J, Lee NA, et al. Eosinophil degranulation in the allergic lung of mice primarily occurs in the airway lumen. *J Leukoc Biol*. (2017) 101:75–81. doi: 10.1128/JLB.1001710-177

89. Berends ET, Horswill AR, Haste NM, Monestier M, Nizet V, Von Kockritz-Blickwede M. Nuclease expression by *Staphylococcus aureus* facilitates escape from neutrophil extracellular traps. *J Innate Immun.* (2010) 2:576–86. doi: 10.1159/000319909

90. De Buhr N, Neumann A, Jerjomiceva N, von Kockritz-Blickwede M, Baums CG. *Streptococcus suis* DNoase SnAa contributes to degradation of neutrophil extracellular traps (NETs) and evasion of NET-mediated antimicrobial activity. *Microbiology* (2014) 160:385–95. doi: 10.1099/mic.0.072199-0

91. Vrbanic S, Vinterin T, Heiling PW, Jirsenis M, Acke F, Van Cauwenberge P, et al. The importance of local eosinophils in the surgical outcome of chronic rhinosinusitis: a 3-year prospective observational study. *Am J Rhinol Allergy* (2014) 28:260–4. doi: 10.2500/ajra.2014.28.4024
108. Healy DY, Leid JG, Sanderson AR, Hunsaker DH. Biofilms with fungi in chronic rhinosinusitis. *Otolaryngol Head Neck Surg.* (2008) 138:641–7. doi: 10.1016/j.ototns.2008.02.002

109. Dunican EM, Elicker BM, Gierada DS, Nagle SK, Schiebler ML, Newell JD, et al. Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction. *J Clin Invest.* (2018) 128:997–1009. doi: 10.1172/JCI95693

110. Uller L, Persson CG, Kallstrom L, Erjefalt JS. Lung tissue eosinophils may be cleared through luminal entry rather than apoptosis: effects of steroid treatment. *Am J Respir Crit Care Med.* (2001) 164:1948–56. doi: 10.1164/ajrccm.164.10.2011135

111. Neves JS, Perez SA, Spencer LA, Melo RC, Reynolds L, Ghiran I, et al. Eosinophil granules function extracellularly as receptor-mediated secretory organelles. *Proc Natl Acad Sci USA.* (2008) 105:18478–83. doi: 10.1073/pnas.0804547105

112. Persson C, Uller L. Theirs but to die and do: primary lysis of eosinophils and free eosinophil granules in asthma. *Am J Respir Crit Care Med.* (2014) 189:628–33. doi: 10.1164/rccm.201311-2069OE

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.